Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their OptionsPRNewsWire • 03/18/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)Business Wire • 03/17/23
YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023PRNewsWire • 03/17/23
YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 03/16/23
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 03/15/23
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMABPRNewsWire • 03/15/23
YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 03/15/23
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)PRNewsWire • 03/15/23
YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. ShareholdersPRNewsWire • 03/14/23
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 03/13/23
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 03/13/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMABPRNewsWire • 03/13/23
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively ParticipateBusiness Wire • 03/13/23
Y-MABS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their OptionsPRNewsWire • 03/11/23
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABPRNewsWire • 03/09/23
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABPRNewsWire • 03/01/23
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABPRNewsWire • 02/23/23
Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMABPRNewsWire • 02/22/23
NATIONALLY RANKED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - YMABNewsfile Corp • 02/17/23
YMAB LOSS ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABPRNewsWire • 02/16/23
Y-mAbs Class Action: Levi & Korsinsky Reminds Y-mAbs Therapeutics, Inc. Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of March 20, 2023 - YMABNewsfile Corp • 02/16/23
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/16/23
Y-MABS THERAPEUTICS, INC. (YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)Newsfile Corp • 02/16/23
YMAB INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Lawsuit PendingNewsfile Corp • 02/15/23
